Back to search

Netherlands· NL-d5a820ea261d

Ethosuximide Strides 250 mg zachte capsules

A ethosuximide product containing ethosuximide, registered in Netherlands by Strides Pharma (Cyprus) Limited. The same ATC class is registered in 16 of our 19 countries.

ATC N03AD01

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedEthosuximide Strides 250 mg zachte ca…ATCN03AD01REGISTER NO.NL-d5a820ea261dPACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Ethosuximide is registered in 16 of 19 countries.

Countries holding a registration under ATC N03AD01 (ethosuximide), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose

Ethosuximide · ATC N03AD01

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ethosuximide costs, country by country.

Normalised to the WHO defined daily dose (1.25 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Ethosuximide · price per daily dose (1.25 g)

USD · FX 28 Sept 2026

  • CH Switzerland$1.83
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
ETHOSUXIMIDE
Manufacturer
Strides Pharma (Cyprus) Limited
Country
Netherlands (NL)
ATC code
N03AD01
ATC class
Ethosuximide
Defined daily dose
1.25 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    123574

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

124 interactions on record for ethosuximide.

Graded by severity as the source publishes them — 124 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Ethosuximide · interactions on record

124 records

  • 124 moderate

Most severe, free to view

  • MetoclopramideA03FA01moderate
  • ThiethylperazinA04AB03moderate
  • DiphenhydraminA04AB05moderate
  • DronabinolA04AD10moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ethosuximide in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ethosuximide products

Authorised across Europe · EMA

The same active substance is authorised in 18 EEA countries. Names it is sold under:

  • Austria · Ethosuximid Neuraxpharm, Petinimid
  • Belgium · Zarontin
  • Bulgaria · Petinimid
  • Czechia · Petinimid
  • Germany · Ethosuximid Glenmark, Ethosuximid Neuraxpharm
  • Denmark · Ethosuximide Orifarm, Ethosuximide Strides
  • Spain · Etosuximida Faes
  • France · Zarontin
  • United Kingdom (Northern Ireland) · Emeside, Epesri
  • Croatia · Suxital
  • Ireland · Zarontin
  • Italy · Etosuccimide Glenmark, Zarontin
  • Luxembourg · Zarontin
  • Norway · Ethosuximide Orifarm, Ethosuximide Strides
  • Poland · Petinimid
  • Sweden · Ethosuximide Orifarm, Ethosuximide Strides
  • Slovenia · Suxital
  • Slovakia · Petinimid Cps, Petnidan

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9e23b47f-161d-4166-87f8-c6a25eaf5b31
GET /v1/drugs/9e23b47f-161d-4166-87f8-c6a25eaf5b31?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, zacht",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h123574_smpc.pdf",
  "strength": null,
  "atc_label": "Ethosuximide",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg123574",
  "excipients": [
    "ERYTHROSINE (E 127)",
    "GELATINE (E 441)",
    "GLYCEROL (E 422)",
    "MACROGOL 400",
    "SORBITOL, VLOEIBAAR, NIET-KRISTALLISEERBAAR (E 420)",
    "WATER, GEZUIVERD"
  ],
  "substances": [
    "ETHOSUXIMIDE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h123574.pdf",
  "authorised_at": "2019/08/21",
  "procedure_number": "NL/H/4514/001",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "123574",
  "additional_monitoring": "N"
}

See everything about ethosuximide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.